H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $100 from $115 and keeps a Buy rating on the shares. The firm sees Korro “as somewhat insulated from the market turmoil that rocked genetic medicines stocks this week.” While the was down as much as 26% in response to Vinay Prasad’s FDA appointment, this was mostly unwarranted, as KRRO-110 will not be reviewed by Dr. Prasad’s division, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Strategic Workforce Restructuring and Clinical Advancements Justify Buy Rating for Korro Bio
- Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)
- Korro Bio Announces Strategic Workforce Reduction Plan
- Korro Bio initiated with an Overweight at Cantor Fitzgerald
- Korro Bio initiated with a Buy at Chardan
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue